期刊文献+

基因多态性对巯嘌呤类药物作用影响的研究进展 被引量:2

Recent progress in research and development of the impact of gene polymorphisms on thiopurine drugs
下载PDF
导出
摘要 基因多态性是影响巯嘌呤类药物在体内代谢,最终造成药物疗效和毒性差异的主要原因。近年来研究发现,单一药物代谢酶或转运体的基因多态性与巯嘌呤类药物临床不良反应不完全相关,而多基因分析可能更好地解释患者对该药的不耐受原因。本文介绍了多种与巯嘌呤类药物有关的酶基因多态性的研究情况,同时就其代谢特点及与该药敏感性的关系进行综述。 Gene polymorphisms affect the metabolisms of thiopurine drugs, which eventu- ally become the main reason for the differences in efficacy and toxicity. Recently some resear- ches have showed that there were no complete correlations between a single gene polymorphism of drug metabolizing enzyme or transporter and clinical adverse reactions of thiopurine drugs. However, the reasons of drug intolerance wereprobably more related to multi-genetic analyses. In this article, some of the recent developments of gene polymorphisms of several enzymes about thiopurine drugs were introduced. Meanwhile, the relationships between their metabolic charac- teristics and drug susceptibility were reviewed.
作者 谢偲 岳丽杰
出处 《中国临床药理学与治疗学》 CAS CSCD 2014年第7期818-824,共7页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 国家自然科学基金资助项目(30471830) 深圳市科技计划重点项目(20110101)
关键词 巯嘌呤 基因多态性 药物代谢酶 药物转运体 thiopurine gene polymorphism drug metabolizing enzyme drug transporter
  • 相关文献

参考文献40

  • 1Evans W, Mcleod HL. Pharmacogenomics-drug disposition, drug targets and side effects[J]. N Engl J Med, 2003, 348(6): 538-549.
  • 2Dubinsky MC, Lamothe S, Yang HY, et al. Phar macogenomicsand metabolite measurement for 6 mercaptopurine therapy in inflammatory bowel dis ease[J]. Gastroenterology, 2000, 18(4): 705 - 713.
  • 3Peregud-Pogorzelski J, Tetera-Rudnicka E, Kurza- wski M, et al. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during ma- intenance therapy: the Polish multicenter analysis [J]. Pediatr Blood Cancer, 2011, 57(4): 578- 582.
  • 4Armstrong L, Sharif JA, Galloway P, et al. Evalu ating the use of metabolite measurement in chil dren receiving treatment with a thiopurine[J]. All ment Pharmacol Ther, 2011, 34(9): 1106-1114.
  • 5Uribe-Luna S, Quintana-Hau JD, Maldonado-Ro- driguez R, et al. Mutagenic consequences of the incorporation of 6-thioguanine into DNA[J]. Bio- chem Pharmacol, 1997, 54(3) :419-424.
  • 6Hedeland RL, Hvidt K, Nersting J, et al. DNA in- corporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lympho- blastic leukaemia and non-Hodgkin lymphoma[J]. Cancer Chemother Pharmaeol, 2010, 66(3): 485- 491.
  • 7Bokkerink JP, Stet EH, De Abreu RA, et al. 6- mercaptopurine : cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts [J]. Biochem Pharmacol, 1993, 45 (7): 1455- 1463.
  • 8Eklund BI, Moberg M, Bergquist J, et al. Diver- gent activities of human glutathione transferases in the bioactivation of azathioprine[J]. Mol Pharma- col, 2006, 70(2): 747-754.
  • 9Stocco G, Martelossi S, Barabino A, et al. Gluta- thione-S-transferase genotypes and the adverse effects of azathioprine in young patients with in-flammatory bowel disease[J]. Inflamm Bowel Dis, 2007, 13(1): 57-64.
  • 10Stocco G, Cuzzoni E, De Iudicibus S, et al. Dele- tion of glutathione-S-transferase M1 reduces aza- thioprine metabolite concentrations in young pa- tients with inflammatory bowel disease[J]. J Clin Gastroenterol, 2014, 48(1): 43-51.

二级参考文献4

共引文献2

同被引文献12

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部